Journal of Translational Autoimmunity最新文献

{"title":"PNPLA3 I148 M genetic variant in autoimmune hepatitis characterises advanced disease at diagnosis and reduced survival free of cirrhotic events and liver-related mortality","authors":"Kalliopi Azariadis ,&nbsp;Nikolaos K. Gatselis ,&nbsp;Aggeliki Lyberopoulou ,&nbsp;Pinelopi Arvaniti ,&nbsp;Kalliopi Zachou ,&nbsp;Stella Gabeta ,&nbsp;George N. Dalekos","doi":"10.1016/j.jtauto.2024.100243","DOIUrl":"https://doi.org/10.1016/j.jtauto.2024.100243","url":null,"abstract":"<div><h3>Background</h3><p>Autoimmune hepatitis (AIH) is a relatively rare autoimmune disease with a strong genetic background. The patatin-like phospholipase domain-containing protein 3 (<em>PNPLA3</em>) <em>I148 M</em> (<em>rs7</em>38409 C/G) variant has been associated with hepatic inflammation and fibrosis in chronic hepatic diseases beyond metabolic dysfunction-associated steatotic liver disease (MASLD).</p></div><div><h3>Aim</h3><p>Our aim was to investigate the significance of <em>PNPLA3 I148 M</em> variant in AIH.</p></div><div><h3>Method</h3><p>Two hundred AIH patients, followed in our centre, were evaluated while 100 healthy subjects served as controls. Genotyping was performed with allelic discrimination end-point polymerase chain reaction (PCR).</p></div><div><h3>Results</h3><p>The <em>I148 M</em> variant was present in 95/200 (47.5 %) AIH patients compared to 47/100 (47 %) healthy controls (p = 1.000). Patients with GG/CG genotypes were more likely to present with decompensated cirrhosis at diagnosis (GG/CG 6.3 % vs. CC 1 %, p = 0.039). Comorbidity with cardiometabolic risk factors and concurrence of MASLD was similar across genotypes. Simple steatosis was present in 37/186 (19.9 %) and steatohepatitis in 14/186 (7.5 %) patients with available liver biopsy without correlation with <em>PNPLA3</em> genotype. Fibrosis stage and grade of inflammation were not correlated with any genotype. Response to treatment was also independent of the presence of the <em>I148 M</em> variant, even though a longer time was needed to achieve complete biochemical response in those carrying the GG/CG genotypes (p = 0.07). On Kaplan Meier analysis homozygosity for the G allele corelated with reduced survival free of decompensation (p = 0.006), cirrhotic events (decompensation, liver transplantation, hepatocellular carcinoma; p = 0.001) and liver-related death or liver transplantation (p = 0.011) in treated patients.</p></div><div><h3>Conclusions</h3><p>The <em>PNPLA3 I148 M</em> variant in AIH patients is associated with increased risk of advanced disease at diagnosis and reduced survival free of cirrhotic events and liver-related death or liver transplantation, regardless of the presence of MASLD. This signifies a potential role for the <em>PNPLA3 I148 M</em> variant as a new AIH biomarker allowing to identify patients at increased risk of disease progression.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"9 ","pages":"Article 100243"},"PeriodicalIF":3.9,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589909024000133/pdfft?md5=88106cddb30fad94504e751c77e514d0&pid=1-s2.0-S2589909024000133-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141325237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The new era of immune skin diseases: Exploring advances in basic research and clinical translations","authors":"Bo Zhang ,&nbsp;Xiaole Mei ,&nbsp;Ming Zhao ,&nbsp;Qianjin Lu","doi":"10.1016/j.jtauto.2024.100232","DOIUrl":"10.1016/j.jtauto.2024.100232","url":null,"abstract":"","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"8 ","pages":"Article 100232"},"PeriodicalIF":3.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589909024000029/pdfft?md5=fe40277a1fbc700802b0cd52f1aac353&pid=1-s2.0-S2589909024000029-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139539963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial from the new editor-in-chief","authors":"Yves Renaudineau","doi":"10.1016/j.jtauto.2023.100224","DOIUrl":"10.1016/j.jtauto.2023.100224","url":null,"abstract":"","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"8 ","pages":"Article 100224"},"PeriodicalIF":3.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589909023000370/pdfft?md5=ceca85d18551d4eb2075c6d003907f99&pid=1-s2.0-S2589909023000370-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138608307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triptolide regulates neutrophil function through the Hippo signaling pathway to alleviate rheumatoid arthritis disease progression","authors":"Pengyuan Liu ,&nbsp;Huiyang Liu ,&nbsp;Yali Sang ,&nbsp;Lingyan Zhu ,&nbsp;Peiyao Zhang ,&nbsp;Chunyan Pang ,&nbsp;Yongfu Wang ,&nbsp;Li Bai","doi":"10.1016/j.jtauto.2024.100242","DOIUrl":"https://doi.org/10.1016/j.jtauto.2024.100242","url":null,"abstract":"<div><p>Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammatory changes in the joints, the etiology of which is unclear. It is now well established that regulated cell death (RCD) and migration of neutrophils play an important role in the pathogenesis of RA. Tripterygium wilfordii Hook.f (TwHF) is a total saponin extracted from the root of Tripterygium wilfordii Hook.f, a plant of the family Wesleyanaceae, which has strong anti-inflammatory and immunomodulatory effects and has been used as a basic drug in the clinical treatment of RA. Despite the good efficacy of TwHF treatment, the mechanism of action of TwHF remains unclear. Several studies have demonstrated that the drug tripterygium glycosides, in which TwHF is the main ingredient, has achieved excellent efficacy in the clinical treatment of RA. Investigations have also found that TwHF can affect cellular RCD, cell migration, cell proliferation, and the apoptosis-related Hippo signaling pathway. In this study, we first analyzed the RCD and migration differences of neutrophils in patients with RA through network pharmacology and transcriptome analysis. Subsequently, we used electron microscopy, immunofluorescence, and other methods to identify the RCD phenotype of neutrophils. In collagen-induced arthritis (CIA) model, we demonstrated that Triptolide (the main active ingredient in TwHF) could alleviate the progression of arthritis by reducing the bone destruction and the infiltration of neutrophils. Furthermore, in vitro experiments showed that Triptolide induced neutrophil apoptosis, inhibited the formation of neutrophil extracellular traps (NETs), and impeded the neutrophil migration process in a Hippo pathway-dependent manner. Taken together, these findings indicate that Triptolide has potential for treating RA and provide theoretical support for the clinical application of TwHF, as a traditional Chinese medicine, in RA.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"8 ","pages":"Article 100242"},"PeriodicalIF":3.9,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589909024000121/pdfft?md5=2ca56dddf1ab03029724871214bfa00d&pid=1-s2.0-S2589909024000121-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140894458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stem cell-based therapy for systemic lupus erythematous","authors":"Maryam Zare Moghaddam ,&nbsp;Mohammad Javad Mousavi ,&nbsp;Somayeh Ghotloo","doi":"10.1016/j.jtauto.2024.100241","DOIUrl":"https://doi.org/10.1016/j.jtauto.2024.100241","url":null,"abstract":"<div><p>Systemic lupus erythematosus (SLE), an autoimmune disease, is among the most prevalent rheumatic autoimmune disorders. It affects autologous connective tissues caused by the breakdown of self-tolerance mechanisms. During the last two decades, stem cell therapy has been increasingly considered as a therapeutic option in various diseases, including parkinson's disease, alzheimer, stroke, spinal cord injury, multiple sclerosis, inflammatory bowel disease, liver disease, diabete, heart disease, bone disease, renal disease, respiratory diseases, and hematological abnormalities such as anemia. This is due to the unique properties of stem cells that divide and differentiate to the specialized cells in the damaged tissues. Moreover, they impose immunomodulatory properties affecting the diseases caused by immunological abnormalities such as rheumatic autoimmune disorders.</p><p>In the present manuscript, efficacy of stem cell therapy with two main types of stem cells, including mesenchymal stem cell (MSC), and hematopoietic stem cells (HSC) in animal models or human patients of SLE, has been reviewed. Taken together, MSC and HSC therapies improved the disease activity, and severity in kidney, lung, liver, and bone (improvement in the clinical manifestation). In addition, a change in the immunological parameters occurred (improvement in immunological parameters). The level of autoantibodies, including antinuclear antibody (ANA), and anti-double-stranded deoxyribonucleic acid antibodies (dsDNA Abs) reduced. A conversion of Th1/Th2 ratio (in favor of Th2), and Th17/Treg (in favor of Treg) was also detected.</p><p>In spite of many advantages of MSC and HSC transplantations, including efficacy, safety, and increased survival rate of SLE patients, some complications, including recurrence of the disease, occurrence of infections, and secondary autoimmune diseases (SAD) were observed after transplantation that should be addressed in the next studies.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"8 ","pages":"Article 100241"},"PeriodicalIF":3.9,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S258990902400011X/pdfft?md5=0d896829d5e6809db86fa1a4317838e3&pid=1-s2.0-S258990902400011X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140824266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes upon the gluten-free diet of HLA-DQ2 and TRAFD1 gene expression in peripheral blood of celiac disease patients","authors":"Mariavittoria Laezza ,&nbsp;Laura Pisapia ,&nbsp;Benedetta Toro ,&nbsp;Vincenzo Mercadante ,&nbsp;Antonio Rispo ,&nbsp;Carmen Gianfrani ,&nbsp;Giovanna Del Pozzo","doi":"10.1016/j.jtauto.2024.100240","DOIUrl":"https://doi.org/10.1016/j.jtauto.2024.100240","url":null,"abstract":"<div><h3>Background</h3><p>Celiac disease (CD) is a chronic immuno-mediated enteropathy caused by dietary gluten in genetically susceptible individuals carrying HLA (Human Leukocytes Antigen) genes that encode for DQ2.5 and DQ8 molecules. TRAFD1 (TRAF-type zinc finger domain 1) is a gene recently found associated with CD and defined as a master regulator of IFNγ signalling and of MHC class I antigen processing/presentation. There is no specific drug therapy and the only effective treatment is the gluten-free diet (GFD). The great majority of celiac patients when compliant with GFD have a complete remission of symptoms and recovery of gut mucosa architecture and function. Until now, very few studies have investigated molecular differences occurring in CD patients upon the GFD therapy.</p></div><div><h3>Methods</h3><p>We looked at the expression of both HLA DQ2.5 and TRAFD1 risk genes in adult patients with acute CD at the time of and in treated patients on GFD. Specifically, we measured by qPCR the HLA-DQ2.5 and TRAFD1 mRNAs on peripheral blood mononuclear cells (PBMC) from the two groups of patients.</p></div><div><h3>Results</h3><p>When we compared the HLA-DQ mRNA expression, we didn't find significant variation between the two groups of patients, thus indicating that GFD patients have the same capability to present gliadin antigens to cognate T cells as patients with active disease. Conversely, TRAFD1 was more expressed in PBMC from treated CD subjects. Notably, TRAFD1 transcripts significantly increased in the patients analyzed longitudinally during the GFD, indicating a role in the downregulation of gluten-induced inflammatory pathways.</p></div><div><h3>Conclusion</h3><p>Our study demonstrated that HLA-DQ2.5 and TRAFD1 molecules are two important mediators of anti-gluten immune response and inflammatory process.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"8 ","pages":"Article 100240"},"PeriodicalIF":3.9,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589909024000108/pdfft?md5=79724f389316f7231ca084c490b40186&pid=1-s2.0-S2589909024000108-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140650389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoantibodes to GP210 are a metric for UDCA responses in primary biliary cholangitis","authors":"Chan Wang ,&nbsp;Zhuye Qin ,&nbsp;Mingming Zhang ,&nbsp;Yaping Dai ,&nbsp;Luyao Zhang ,&nbsp;Wenyan Tian ,&nbsp;Yuhua Gong ,&nbsp;Sufang Chen ,&nbsp;Can Yang ,&nbsp;Ping Xu ,&nbsp;Xingjuan Shi ,&nbsp;Weifeng Zhao ,&nbsp;Suraj Timilsina ,&nbsp;M. Eric Gershwin ,&nbsp;Weichang Chen ,&nbsp;Fang Qiu ,&nbsp;Xiangdong Liu","doi":"10.1016/j.jtauto.2024.100239","DOIUrl":"https://doi.org/10.1016/j.jtauto.2024.100239","url":null,"abstract":"<div><h3>Objectives</h3><p>Antibodies to gp210 and sp100 are specific and unique anti-nuclear autoantibodies (ANAs) associated with primary biliary cholangitis (PBC). Importantly the presence of anti-gp210 and anti-sp100 responses is indicative of poor clinical outcomes. However, the utility of measuring titers of these antibodies remains unclear.</p></div><div><h3>Materials and methods</h3><p>Using the in-house purified gp210 (HSA108-C18) and sp100 (amino acid position 296–386), we quantitatively measured serum autoantibodies to gp210 and sp100 using chemiluminescence immunoassay (CLIA) in a very large cohort of 390 patients with PBC, including 259 cases with no prior ursodesoxycholic acid (UDCA) treatment and 131 cases with UDCA treatment. We also analyzed serial changes in anti-gp210 and anti-sp100 levels in 245 sequential samples from 88 patients.</p></div><div><h3>Results</h3><p>In our cross-sectional analysis, we detected anti-gp210 immunoglobulin G (IgG) and anti-sp100 IgG autoantibodies in 129 out of 390 (33.1%) and 80 out of 390 (20.5%) PBC patients, respectively. Multivariate analysis revealed that serum IgG (st.β = 0.35, <em>P</em> = 0.003) and gamma-glutamyltransferase (GGT) (st.β = 0.23, <em>P</em> = 0.042) levels at baseline were independently associated with anti-gp210 concentrations. In serial testing, we observed significant fluctuations in anti-gp210 antibody levels. These fluctuations reflected responsiveness to UDCA therapy, particularly in anti-gp210-positive patients with initially lower concentrations in the stages of disease.</p></div><div><h3>Conclusions</h3><p>Our study reflects that quantitative changes of anti-gp210 antibody are indicative of UDCA responses. There is a great need for newer metrics in PBC and we suggest that a more detailed and longer study of these unique ANAs is warranted.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"8 ","pages":"Article 100239"},"PeriodicalIF":3.9,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589909024000091/pdfft?md5=122fa1d258d4e30ca9277942c974682d&pid=1-s2.0-S2589909024000091-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140191712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of non-systemic Sjögren's syndrome: Potential prevention of systematization with immunosuppressant agent/biotherapy","authors":"Aude Belbézier ,&nbsp;Thi Thu Thuy Nguyen ,&nbsp;Mélanie Arnaud ,&nbsp;Bruna Ducotterd ,&nbsp;Marie Vangout ,&nbsp;Alban Deroux ,&nbsp;Catherine Mansard ,&nbsp;Françoise Sarrot-Reynauld ,&nbsp;Laurence Bouillet","doi":"10.1016/j.jtauto.2024.100238","DOIUrl":"https://doi.org/10.1016/j.jtauto.2024.100238","url":null,"abstract":"<div><h3>Background</h3><p>Sjögren's syndrome (SS) is a systemic autoimmune pathology manifested mainly by a dry syndrome, intense asthenia and arthromyalgia. Systemic manifestations may also occur. Since 2019, immunosuppressant agents (IS) or biotherapies are recommended only for patients with systemic involvement. However, before 2019, in some cases, paucisymptomatic patients had been treated with IS/biotherapies, often off-label. <strong>Objective</strong>: We propose to evaluate the benefit and safety of using IS/biotherapy in patients with SS without systemic involvement. <strong>Methods:</strong> We retrospectively collected the clinical records of all patients with SS diagnosed according to ACR/EULAR diagnostic criteria followed up between January 1980 and October 2023 at Grenoble University Hospital (France). <strong>Results:</strong> Eighty-three patients were included: 64 with an initially non-systemic form. Of these patients with an initially non-systemic form, 24 were treated with IS/biotherapy. None of them developed secondary systematization, whereas 11 out of 40 patients in the untreated group did (p &lt; 0.05). On the other hand, IS/biotherapy did not appear to improve dry syndrome. There were no serious adverse events. <strong>Conclusion:</strong> Early introduction of an IS/biotherapy treatment appears to provide a benefit for the patient without side effects.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"8 ","pages":"Article 100238"},"PeriodicalIF":3.9,"publicationDate":"2024-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S258990902400008X/pdfft?md5=2941ee00a1b6c48966a06947f00da1c8&pid=1-s2.0-S258990902400008X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140069353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoimmunity in centenarians. A paradox","authors":"Juan-Manuel Anaya ,&nbsp;Ivan David Lozada-Martinez ,&nbsp;Isaura Torres ,&nbsp;Yehuda Shoenfeld","doi":"10.1016/j.jtauto.2024.100237","DOIUrl":"https://doi.org/10.1016/j.jtauto.2024.100237","url":null,"abstract":"<div><p>Autoimmune diseases (ADs) are one of the groups of chronic illnesses that impose a significant burden of disease and health costs worldwide. Age is a crucial risk factor for the onset of ADs. Theoretically, it is inferred that with organic and immune system aging, the loss of immune tolerance and specificity of immune activity becomes more intense, the probability of autoimmunity is increasing. However, there is a group of individuals whose prevalence of ADs is very low or non-existent, despite the biological aging. This paradox in autoimmunity raises questions. Centenarians, individuals who are over 100 years old, are possibly the most successful model of biological aging in humans. Most of these individuals exhibit a favorable health phenotype. To date, primary data evidence and potential hypotheses explaining this phenomenon are lacking globally, even though this paradox could provide valuable, original, and relevant information regarding the understanding of risk or protective factors, biological drivers, and biomarkers related to autoimmunity. Herein we discuss some hypothesis that may explain the absence of ADs in centenarians, including inflammaging, immunosenescence and immune resilience, immune system hyperstimulation, proteodynamics, and genetics.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"8 ","pages":"Article 100237"},"PeriodicalIF":3.9,"publicationDate":"2024-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589909024000078/pdfft?md5=d73ac460af023a75956b96beaf06a48e&pid=1-s2.0-S2589909024000078-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140030332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of omega-3 fatty acids supplementation on hemoglobin, hematocrit, and platelet levels of patients with ESRD condition undergoing dialysis","authors":"Zahra Mahmoudi ,&nbsp;Zahra Roumi ,&nbsp;Seyed Ali Askarpour ,&nbsp;Zahra Mousavi ,&nbsp;Hanieh Shafaei ,&nbsp;Neda Valisoltani ,&nbsp;Mahsa Shapouri ,&nbsp;Seyed Reza Mirshafaei ,&nbsp;Pouya Mirzaee ,&nbsp;Khadijeh Abbasi Mobarakeh ,&nbsp;Elahe Taghavi Sufiani ,&nbsp;Zeinab Motiee Bijarpasi ,&nbsp;Zeynab Motiei ,&nbsp;Masoud Khosravi ,&nbsp;Saeid Doaei ,&nbsp;Maryam Gholamalizadeh","doi":"10.1016/j.jtauto.2024.100233","DOIUrl":"https://doi.org/10.1016/j.jtauto.2024.100233","url":null,"abstract":"<div><h3>Background</h3><p>Concomitant inflammation may boost the cardiovascular complications in end-stage renal disease (ESRD) patients undergoing hemodialysis (HD). Omega-3 fatty acids may have certain health benefits in HD patients. The aim of this study was to investigate the effects of omega-3 fatty acids supplementation on hematocrit (HCT), hemoglobin (HB) level and platelet (PLT) counts of HD patients.</p></div><div><h3>Methods</h3><p>A randomized controlled trial was conducted on HD patients at a private dialysis center in Rasht, Iran. Three omega-3 fatty acid supplement capsules (3 g/d) were administered daily for two months to patients in the intervention group (n = 55). The control group (n = 60) were given three placebo capsules containing medium chain triglyceride (MCT) oil, similar to the supplemental dose of the intervention group at the same period. Three parameters of HCT, HB and PLT were measured at baseline and after the intervention.</p></div><div><h3>Results</h3><p>The PLT count decreased in the intervention group compared to the control group (173.38 ± 74.76 vs. 227.68 ± 86.58 10³/mm³, F = 4.83, P = 0.03). No significant change was found on the levels of HCT and HB parameters between the two groups after the intervention.</p></div><div><h3>Conclusion</h3><p>Omega-3 supplementation in HD patients may decrease the risk of forming blood clots in the blood vessels. Further studies are warranted.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"8 ","pages":"Article 100233"},"PeriodicalIF":3.9,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589909024000030/pdfft?md5=5bcba8760b794c6c65baed779d81fc5c&pid=1-s2.0-S2589909024000030-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140030333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}